Company intelligence / Profile preview
Shuttle Pharmaceuticals
Gaithersburg, Maryland, United Statesshuttlepharma.com ↗
- Ownership
- Public · SHPH
- Employees
- ~11-50
- Development stage
- Other
01
Overview
Currently conducting a Phase II study of Ropidoxuridine + RT in IDH wild-type, methylation negative glioblastoma patients. The IND has been approved with FDA issuing a safe to proceed letter. Enrollment is anticipated to require 12-18 months with early results expected in approximately 24 months.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesRadiation sensitizersHDAC inhibitors
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Georgetown University
04
Financials
- Market cap
- $24M
- Total revenue
- $0
- Enterprise value
- $24.1M
Beyond the preview
Go deeper on Shuttle Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shuttle Pharmaceuticals.